Brand Refactoring: "Compulsory Approval for Dong Sung Pharmaceutical Is Not a Simple Card—Creditors' and Shareholders' Opposition Are Separate Rights" View original image

Regarding the controversy surrounding the Dong Sung Pharmaceutical rehabilitation plan, the largest shareholder, Brand Refactoring, stated on March 16 that the opposition of rehabilitation creditors and shareholders are independent rights issues and should not be viewed simply as a matter of for or against.


Brand Refactoring explained, "With the stakeholders' meeting scheduled for the 18th, there is growing interest in the Dong Sung Pharmaceutical rehabilitation plan. However, the current opposition arises from the separate interests of the groups of rehabilitation creditors and shareholders," adding, "It is not appropriate to interpret the rights and property issues of these two groups as a single stream of opposition."


It was also analyzed that the actions of minority shareholders are an extension of these issues. In fact, some minority shareholders are holding rallies in front of the Financial Supervisory Service, demanding verification of the rehabilitation procedure and the acquisition process, arguing that these could undermine the value and rights of existing shareholders' stakes.


The company also emphasized the need for caution regarding the possibility of a compulsory approval during the rehabilitation process. Brand Refactoring stated, "Article 244 of the Debtor Rehabilitation and Bankruptcy Act allows the court to approve a rehabilitation plan with protective provisions for rights, even if some groups do not meet the consent requirements." However, they added, "This is strictly an exceptional provision, and the Supreme Court also recognizes that compulsory approval is a matter of judicial discretion."


They continued, "Compulsory approval is not a general procedure to easily override opposing stakeholders; rather, it is a tool that is considered only under strict requirements and in limited circumstances," adding, "Whether the court can exercise this authority should be determined based on the level of rights protection in each individual case."


The company also explained the funding structure included in the rehabilitation plan. According to the released plan, the funds for normalizing Dong Sung Pharmaceutical amount to 160 billion won, consisting of a 70 billion won paid-in capital increase, 50 billion won in convertible bonds (CB), and 40 billion won in corporate bonds.


Brand Refactoring stated, "The total amount of 160 billion won may appear to be new capital inflow, but structurally, the bond-type funds such as convertible bonds and corporate bonds account for as much as 90 billion won," adding, "In reality, there is a possibility that the company will have to bear both financial costs and repayment burdens going forward."


They also noted that the market needs to interpret the conditions of the convertible bonds in particular. The CB in question is reportedly structured with a three-year maturity, a 6% annual coupon rate, and a 10% compound annual maturity rate. The conversion price is 1,000 won. In addition, a refixing clause is included, and investors are granted a put option for early redemption after two years.


Brand Refactoring explained, "The coupon rate alone may seem low, but in reality, various factors such as the maturity interest rate and early redemption conditions are combined," adding, "It is necessary to consider the overall financial terms that the company will be required to bear in the future."


They emphasized that the core criterion for judgment in this case should not be a simple vote count, but rather whether rights are being protected. Brand Refactoring stated, "The essence of the stakeholders' meeting is not about which side wins more votes, but whether the rights of opposing rehabilitation creditors and shareholders are being substantively protected," adding, "Compulsory approval is an exceptional authority granted only under conditions that minimize infringement on the property rights of other stakeholders."



They added, "The significance of the stakeholders' meeting on the 18th will also go beyond a simple for-or-against result and become a process in which the court determines whether these conditions have been met."


This content was produced with the assistance of AI translation services.

© The Asia Business Daily. All rights reserved. Unauthorized AI training and use prohibited.

Today’s Briefing